1. Yanagawa N, Nakhoul F, Kurokawa K, et al. Physiology of phosphorus metabolism. In: Narins RG, editors. Clinical disorders of fluid and electrolyte metabolism. New York, NY: MacGraw Hill; 1994. p.307. -372.
3. Jacquillet G, Unwin RJ. Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi). Pflugers Arch 2019;471:83-98.
4. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983;56:572-581.
5. Biber J, Murer H, Mohebbi N, et al. Renal handling of phosphate and sulfate. Compr Physiol 2014;4:771-792.
6. Bikle D, Adams JS, Christakos S. Vitamin D: Production, metabolism, mechanism of action, and clinical requirements. In: Rosen CJ, editors. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Washington, DC: American Society for Bone and Mineral Research; 2013.
7. Inoue Y, Segawa H, Kaneko I, et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005;390:325-331.
9. Bricker NS. On the pathogenesis of the uremic state. An exposition of the “trade-off hypothesis”. N Engl J Med 1972;286:1093-1099.
10. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
12. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003;12:387-403.
13. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008;74:276-288.
14. Houillier P, Froissart M, Maruani G, et al. What serum calcium can tell us and what it can't. Nephrol Dial Transplant 2006;21:29-32.
15. Grams ME, Chow EK, Segev DL, et al. Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis 2013;62:245-252.
18. Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355-362.
19. Reichel H, Deibert B, Schmidt-Gayk H, et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6:162-169.
20. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38.
21. Isakova T, Wolf MS. FGF23 or PTH: which comes first in CKD? Kidney Int 2010;78:947-949.
22. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975-980.
23. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44:250-256.
24. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-2215.
25. Vervloet MG, Sezer S, Massy ZA, et al. The role of phosphate in kidney disease. Nat Rev Nephrol 2017;13:27-38.
26. De Broe ME. Phosphate: despite advances in research, the benefits to patients remain limited. Kidney Int 2009;75:880-881.
27. Marcuccilli M, Chonchol M, Jovanovich A. Phosphate binders and targets over decades: Do we have it right now? Semin Dial 2017;30:134-141.
29. Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 2018;8:Cd006023.
30. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017;92:26-36.
32. Toussaint ND, Damasiewicz MJ. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms? Nephrology (Carlton) 2017;22 Suppl 2:51-56.
33. Nemeth EF, Goodman WG. Calcimimetic and calcilytic drugs: Feats, flops, and futures. Calcif Tissue Int 2016;98:341-358.
34. Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol 2019;15:109-120.
36. Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014;25:349-360.
39. Seeherunvong W, Abitbol CL, Chandar J, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol 2012;27:2129-2136.
43. Adler AJ, Ferran N, Berlyne GM. Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the “trade-off hypothesis”. Kidney Int 1985;28:932-935.
44. Mace ML, Gravesen E, Nordholm A, et al. Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone In vivo through the FGF receptor in normocalcemia, but not in hypocalcemia. Calcif Tissue Int 2018;102:85-92.
45. Massry SG, Coburn JW, Lee DB, et al. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 1973;78:357-364.
46. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014;10:268-278.
47. Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 2014;85:142-150.
49. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572-586.
51. Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004;43:572-579.
54. Alshayeb HM, Quarles LD. Treatment of chronic kidney disease mineral bone disorder (CKD-MBD). In: Rosen CJ, editors. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Washington, DC: American Society for Bone and Mineral Research; 2013. p.640. -650.
56. Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013;28:352-359.
57. Palcu P, Dion N, Ste-Marie LG, et al. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. Am J Kidney Dis 2015;65:933-936.
59. Macdonald HM, Nishiyama KK, Hanley DA, et al. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int 2011;22:357-362.
60. Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 2018;29:685-697.
61. Besschetnova T, Brooks DJ, Hu D, et al. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis. Bone 2019;124:148-157.
63. Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling. Endocrinology 2016;157:141-149.
64. Drüeke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int 2016;89:289-302.
65. Yamamoto J, Nakazawa D, Nishio S, et al. Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: A pilot study. Ther Apher Dial 2019;
67. Ota M, Takahata M, Shimizu T, et al. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. Osteoporos Int 2017;28:1481-1490.
68. Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007;18:59-68.